|
BioTrinity 2009: Two weeks left to register!
Pfizer is the latest of 13 global pharma companies to register for BioTrinity, sending a Senior Director from its Worldwide Licensing and Business Development Group. Find out which other global pharmas are coming to BioTrinity.
One-to-one meeting requests have surged in the last 24 hours, with literally hundreds of partnering requests made, with a great deal of interest generated by the more than 30 VC and investor delegates, and the excellent biotech and medtech companies which will deliver over thirty 8 minute partnering/corporate presentations on April 2-3. See who else is attending and find out whyBioTrinity has grown even in tough economic climes.
Don't miss out on the biggest and the best yet BioTrinity - in case you haven't seen the most recent agenda, here is a list of the expert panelists and hand-picked innovative and entrepreneurial companies who will be presenting:
Panelists and Chairpeople
Ken Powell, ex CEO, Arrow and Exec. Chairman, Q-Chip
Regina Hodits, Partner, Atlas Venture
Jane Dancer, Vice President Business development, Cellzome
Ian Nicholson, CEO, Chroma Therapeutics
Bruce Savage, CEO, CMP Therapeutics
Mike Wort, MD, De Facto Communications
Mark Ashton, COO, Evotec
David Knowles, Ex-CSO, ex Piramed and CSO of CellCentric
Allison Robbins, Senior Associate, Genzyme Ventures
Kate Burt, Director, Worldwide Transactions, GSK
Esteban Pombo-Villar, Head of Strategic Alliance management, Novartis Institutes of BioMedical Research
Martin Edwards, Senior Partner, Novo Ventures
Anker Lundemose, MD, President, OSI Prosidion
David Mott, Investment Director, Oxford Capital Partners
David Laskow-Pooley, MD, Pharmafor
Fintan Walton, CEO, PharmaVentures
Sam Fazeli, Head of European Equity Research, Piper Jaffray
Nigel Sheail, VP, Global Head of Licensing & Pharma Patnering, Roche
Graeme Martin, President & CEO, Takeda Research Investment, Inc
John Burt, CEO, Thiakis
Company Showcase Speakers
James Noble, CEO, Adaptimmune
Denis Geffroy, Senior Business Manager, Almac Sciences
Keith F Martin, CEO, Apitope
Nigel Parkinson, Account Manager, Aptuit
Andrew Kelly, CSO, Biotecnol
Melanie McCullagh, Director Business Development, Biotica
Chris Atterwill, Scientific And Business Advisor To Capsant, Capsant Neurotechnologies
Nick La Thangue, Founding Director, Celleron Therapeutics
Charles Swingland, Deputy Chairman, Circassia
Paul Davies, CEO, Cytox Group
Eddy Littler, CEO, Domainex
Malcolm Young, CEO, e-Therapeutics plc
Mark Ashton, Executive Vice President, Evotec
Paul Murphy, CEO, Eykona Technologies
Paul Drohan, VP & General Manger, Genzyme UK & Ireland
Simon Jones, Business Development Director, Gilde Pharma
David Scales, CEO, Glycoform
Chris Jones, CEO, Glysure
Malcolm, Weir, CEO, Heptares
John Beadle, Chairman, Hybrid Systems
Carlton Brown, CEO, Immune Targeting Systems
James Noble, CEO, Immunocore
Chris Ullman, CSO, Isogenica
Andrew Lane, MD, MorphoSys
Thomas A. Weaver, Director, MRC Harwell
Nick Housby, CSO, Novolytics
Nick Skaer, CEO, Orthox
John Dawson, CEO, Oxford BioMedica
Richard Broadhead, CEO, Oxford Expression Technologies
Mike Evans, CEO, Oxford Gene Technology
Peter Friend, Director of the Oxford Transplant Centre and Clinical Trial Service Unit
Hadyn Parry, CEO, Oxitec
Christophe Chassagnole, COO, Physiomics Plc
Keith Powell, CEO, Polytherics
Robin Quirk, COO,Director, RegenTec
Wolfgang Edenbeck, Head of Fluorine Team, Saltigo
David Colpman, VP, Shire
Charlie Alexander, Senior Business Development Manager, Shire
Alasdair Naylor, Head of Research, Solace Pharmaceuticals
Finally, Thursday 26th March is the last day you can sign up to join over 100 fellow delegates for the excellent Gala Dinner or the BioTrinity Golf Tournament, although you have until Monday 30th March to sign up for the Pre-conference Networking Reception.
Take a look at the social programme.
Among the 500 delegates expected, there will be delegates from 15 countries will be
present, and 35 corporate presentations will be heard from
companies selected from the Oxford BioCluster, as well as London, Cambridge as well as
Bristol, Southampton, Kent, Nottingham, Manchester and Newcastle,
making BioTrinity a veritable UK
Biotechnology Showcase. Register today and start partnering with the best at BioTrinity 2009
...........................................................................................
What other people think:
"As a direct result of our focused partnering
meetings we introduced proteros to potential clients at BioTrinity
2008 which we are pleased to report resulted in several new
opportunities and one of which has developed into a substantial
business relationship". Gordon J Woodrow, VP at Proteros biostructures GmbH
"My first time at a UK partnering conference was
BioTrinity 2008, and I did a deal with an NZ pharma as a direct
result". Allen Hakimi, Managing Director at Technomark
Life Sciences
"...I would like to congratulate you on an excellent
meeting.."
Tim Haines, Partner, Abingworth
Management
"...Congratulations on such a good event. I had a
very productive day with lots of organized and impromptu meetings -
a very worthwhile event for me." Dr Charles Potter, CEO, Glide Pharma
Read
more testimonials...
Register online now at www.biotrinity.com - hotel accomodation is available
............................................................................................
Thanks to our Sponsors:
............................................................................................
BioTrinity is organised by OBN - Rapidly becoming the
UK's leading biotech network
|
)